174 related articles for article (PubMed ID: 15570074)
1. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
Stoecklein NH; Luebke AM; Erbersdobler A; Knoefel WT; Schraut W; Verde PE; Stern F; Scheunemann P; Peiper M; Eisenberger CF; Izbicki JR; Klein CA; Hosch SB
J Clin Oncol; 2004 Dec; 22(23):4737-45. PubMed ID: 15570074
[TBL] [Abstract][Full Text] [Related]
2. Correlation between different p53 expression patterns and chromosome 17 imbalances in pancreatic ductal adenocarcinoma based on tissue microarray analysis.
Tsiambas E; Kravvaritis C; Tsounis D; Salemis NS; Niotis A; Niotis TH; Rigopoulos DN; Karameris A; Athanasiou AE; Patsouris E; Karakitsos P
J BUON; 2010; 15(1):94-100. PubMed ID: 20414934
[TBL] [Abstract][Full Text] [Related]
3. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
5. EGFR alterations in pancreatic ductal adenocarcinoma: a chromogenic in situ hybridization analysis based on tissue microarrays.
Tsiambas E; Karameris A; Lazaris AC; Talieri M; Triantafillidis JK; Cheracakis P; Manaios L; Gerontopoulos K; Patsouris E; Lygidakis NJ
Hepatogastroenterology; 2006; 53(69):452-7. PubMed ID: 16795991
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling.
Hirono S; Yamaue H; Hoshikawa Y; Ina S; Tani M; Kawai M; Ushijima M; Matsuura M; Saiki Y; Saiura A; Yamamoto J; Miki Y; Noda T
Cancer Sci; 2010 Jan; 101(1):259-66. PubMed ID: 19817750
[TBL] [Abstract][Full Text] [Related]
8. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
9. Chromogenic in situ hybridization analysis of chromosomes 7, 9, and 17 in pancreatic ductal adenocarcinoma based on tissue microarrays.
Tsiambas E; Karameris A; Stamatelopoulos A; Baltayiannis N; Manaios L; Gerontopoulos K; Talieri M; Athanassiou AE; Patsouris E
J BUON; 2006; 11(2):205-11. PubMed ID: 17318972
[TBL] [Abstract][Full Text] [Related]
10. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues.
Rauser S; Weis R; Braselmann H; Feith M; Stein HJ; Langer R; Hutzler P; Hausmann M; Lassmann S; Siewert JR; Höfler H; Werner M; Walch A
Clin Cancer Res; 2007 Sep; 13(17):5115-23. PubMed ID: 17785566
[TBL] [Abstract][Full Text] [Related]
11. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
Bartlett JM; Campbell FM; Mallon EA
Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
[TBL] [Abstract][Full Text] [Related]
12. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
[TBL] [Abstract][Full Text] [Related]
13. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
14. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
[TBL] [Abstract][Full Text] [Related]
16. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique.
Langner C; Gross C; Rehak P; Ratschek M; Rüschoff J; Zigeuner R
Urology; 2005 Jan; 65(1):176-80. PubMed ID: 15667899
[TBL] [Abstract][Full Text] [Related]
17. Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma.
Huang TJ; Huang BJ; Liang QW; Huang CW; Fang Y
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):62-8. PubMed ID: 14969840
[TBL] [Abstract][Full Text] [Related]
18. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.
Schleger C; Verbeke C; Hildenbrand R; Zentgraf H; Bleyl U
Mod Pathol; 2002 Apr; 15(4):462-9. PubMed ID: 11950922
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays.
Tsiambas E; Karameris A; Tiniakos DG; Karakitsos P
Pancreatology; 2007; 7(1):45-52. PubMed ID: 17449965
[TBL] [Abstract][Full Text] [Related]
20. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
